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Introduction
Mental illness affects individuals in all 
age groups and of both sexes. One of 
the main differences in gender when one 
considers treatment of mental illness by 
psychotropic medications is the risk of 
harmful effects that these medications 
can have to the foetus during pregnancy. 
More so, since the most common severe 
psychiatric conditions tend to start in 
young individuals who are of childbearing 
age.1 Thus one needs to be constantly 
aware of the potential presence of a 
pregnancy during the course of illness 
when initiating treatment. This leads to 
possible scenarios that one needs to take 
into consideration.
Prescribing to a woman who is not 
planning pregnancy
In all women of child-bearing age the 
possibilities of a pregnancy should 
be discussed. Many pregnancies are 
unplanned.2 So whatever the plans given 
by the patient, one should always consider 
in this age group the possibilities of 
a pregnancy, and as much as possible 
prescribe accordingly. Thus one should 
as much as possible avoid medications 
that are teratogenic in this age group. In 
psychiatry, for this particular age group 
this applies mostly for patients who suffer 
from Bipolar Affective Disorder. Firstly 
because the antiepileptic medications 
used as mood stabilizers (valproate and 
carbamazepine) are highly teratogenic.3   
Also, due to the particular symptoms 
of hypomania4, unplanned pregnancy is 
not an uncommon consequence. When 
no alternatives to these medications are 
found, the woman should be persistently 
reminded about the possible teratogenic 
consequences, and contraceptive advice 
given. Also, folate should be prescribed. 
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Educational aims
•	 To highlight the differences in prescribing psychotropic medications between the 
genders due to the potential teratogenic effects of psychotropic medications
•	 To show why this needs to be taken into consideration also in females of child bearing  
age that are not planning to get pregnant 
•	 To understand issues that need to be taken into consideration when choosing the 
appropriate  psychotropic medication to use in a pregnant female
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Since most severe psychiatric conditions tend to start in young 
individuals who are of childbearing age, when prescribing 
psychotropic medication one needs to take into consideration the 
difference between males and females due to the potential teratogenic 
effects of psychotropic medication.  This needs to be taken in 
consideration also in females who are not planning a pregnancy 
because of the high number of unplanned pregnancies. In a woman 
who starts to suffer from mental illness during pregnancy, one 
should choose an established drug at the lowest effective dosage. 
In a woman who is taking psychotropic medication and is planning 
a pregnancy, the main issue is whether to discontinue treatment 
or change medication. For this decision, several factors, mainly the 
severity of the condition, and possibility of relapse, should be taken 
into consideration. This is also the case in a woman who is taking 
psychotropic medication and discovers that she is pregnant.
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Table 1 Summary of recommendations of use of psychotropic drugs in pregnancy  
Psychotropic Recommendations
Antidepressants
Tricyclic Antidepressants:5, 6
(Nortryptiline
Amitryptiline
Imipramine)
SSRI’s: Fluoxatine7
Antipsychotics
No clear evidence that any antipsychotic is a major teratogenic 
Preferably use First Generation Antipsychotics: although  safety is 
not fully established but they are considered to have minimal risk 
of teratogenicity8, 9. Most experience being with chlorpromazine, 
haloperidol and trifluoperazine.
Second Generation Antipsychotics : not enough data available, 
Data most available on Olanzapine that seems to be relatively safe in 
respect to congenital malformations10. 
Mood stabilisers
If medication required first consider first generation antipsychotic as 
a mood stabiliser 
Avoid anticonvulsants unless risk and consequences of relapse 
outweigh the known risk of teratogenesis. 
It is recommended that women who potentially can become pregnant 
and are  taking carbamazepine or valproate should receive folic acid as 
prophylaxis 
Sedatives
Ideally use behavioural and psychotherapeutic approaches instead of 
psychotropic medication.
Benzodiazepines are probably not teratogenic but are best avoided in 
late pregnancy11.
A woman who starts to suffer from mental 
illness during pregnancy
Especially during the first trimester, when 
the organs of the foetus are being formed, 
psychotropic medications should be avoided 
as much as possible. Non pharmacological 
methods of treatment should be used as first 
line treatment. But there are instances when 
they are not effective or are not appropriate, 
and so for the mother’s and baby’s safety 
medication has to be used. Here one should 
choose an established drug at the lowest 
effective dosage. This choice arises from 
the fact that double blind clinical trials to 
assess the safety of psychotropic medication 
during pregnancy are obviously unethical 
to perform. So one chooses medication that 
has been used for a long time in pregnant 
women and natural studies have shown that 
the rate of malformations during pregnancies 
in which they were used were not higher 
than malformations occurring spontaneously 
during pregnancies in which no psychotropic 
medication was used. For depression this 
treatment is tricyclic antidepressants. 
The antidepressant of choice in these 
circumstances is Nortryptiline, because 
it is the one with less anticholinergic 
and hypotensive effects. In psychosis, 
the treatment of choice is one of the 
first generation antipsychotics such as 
trifluoprerazine or haloperidol. (See Table 1)
A woman who is taking psychotropic 
medication and is planning a pregnancy
The first thing that should be considered 
in these circumstances is discontinuation 
of medication. In taking this decision 
one needs to take into consideration 
the severity of the condition. In certain 
instances when the mental illness is severe 
Key points
•	 Prescribing psycotropic medication is different in males and females.
•	 In choice of psychotropic medication in all females of child bearing age, due 
consideration must be given to the potential teratogenic effects of the medication.
•	 The decision to prescribe medication during  preganacy is based on balancing between 
the potential risks of relapse and the consequences of mental illness with the potential 
damage of the medication to the foetus.
•	 The mother should be involved in the decision making process. 
•	 When prescribing psychotropic medications for pregnant women,  in general ‘older’ 
medications are preferable to ‘newer’ medications.
and the risk of relapse without medication 
is high, it is unwise to stop medication 
completely. In those instances one should 
switch the medication to one that has much 
lower risk of teratogenicity. In choice of 
such medication the same principles of the 
choice of medication for mental illness that 
arises during pregnancy should be applied. 
When switching to a lower risk medication 
there is always a risk of relapse of the 
condition. Thus switching should be done 
gradually and with close monitoring.
A woman who is taking psychotropic 
medication and discovers that she is 
pregnant
In this instance one needs to decide 
whether to stop medication, to switch it 
to another medication or to continue with 
the present effective medication. There are 
no hard and fast rules, and the first thing 
that needs to be taken into consideration 
is how high would be the risk of relapse 
if medication is discontinued. In severe 
mental illness relapse may ultimately be 
more harmful to the mother and child, than 
the treatment that is being effective to 
control the mental illness. Thus automatic 
abrupt stoppage of medication once the 
woman discovers that she is pregnant 
is not the correct approach. Electro 
Convulsive Therapy can be an alternative or 
adjutant psychotropic medication in some 
pregnancies.
Conclusion
In taking the decisions regarding what 
medication should be used in pregnancy, 
the mother should always be involved in 
the discussion. In this discussion it is 
important that the following issues are 
addressed: 
1. What the potential consequences could 
be if the mother’s mental illness is left 
untreated.  In this discussion, not only 
the impact of this on the mother should 
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be considered, but also the impact of 
this on the newborn;
2. The risks caused by stopping medication 
abruptly;
3. The quality and severity of previous 
episodes, since if relapse occurs it would 
likely be similar to those;
4. What treatment resulted in remission in 
previous episodes;
5. The risk of foetal malformations for 
pregnant women without mental 
disorder;
6. The potential harm that medication can 
do to the foetus during the pregnancy.
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